PT - JOURNAL ARTICLE AU - Roh, Kyoung Ho AU - Kim, Yu Kyung AU - Kim, Shin-Woo AU - Kang, Eun-Rim AU - Yang, Yong-Jin AU - Jung, Sun-Kyung AU - Lee, Sun-Hwa AU - Sung, Nackmoon TI - Coinfection with Respiratory Pathogens in COVID-19 in Korea AID - 10.1101/2020.12.18.20248449 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.18.20248449 4099 - http://medrxiv.org/content/early/2020/12/19/2020.12.18.20248449.short 4100 - http://medrxiv.org/content/early/2020/12/19/2020.12.18.20248449.full AB - Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in upper and lower respiratory specimens and coinfection with other respiratory pathogens in patients with coronavirus disease 2019 (COVID-19) were investigated. From the study subjects (N = 258) retrospectively enrolled when confirmed as SARS-CoV-2 positive, nasopharyngeal (NPS), oropharyngeal swabs (OPS), and sputum specimens were restored for retesting SARS-CoV-2 and detecting respiratory pathogens. Majority of the study subjects (95.7%, N = 247) were confirmed as SARS-CoV-2 positive using NPS/OPS specimens, suggesting that the upper respiratory specimen is most valuable in detecting SARS-CoV-2. Coinfection rates in COVID-19 patients (N = 258) with respiratory pathogens were 9.7% (N = 25); 8.5% (N = 22) respiratory viruses and 1.2% (N = 3) Mycoplasma pneumoniae, an atypical bacterium. Of the respiratory virus coinfection cases (N = 22), 20 (90.9%) were co-infected with a single respiratory virus and 2 (0.8%) (metapneumovirus/adenovirus and rhinovirus/bocavirus 1/2/3/4) with two viruses. Respiratory viruses in single viral coinfection cases with SARS-CoV-2 were as follows: non-SARS-CoV-2 coronaviruses (229E, NL63, and OC43, N = 5, 1.9%), rhinovirus (N = 4, 1.6%), metapneumovirus (N = 3, 1.2%), influenza A (N = 3, 1.2%), respiratory syncytial virus A and B (N = 3, 1.2%), and adenovirus (N = 2, 0.8%). No mixed coinfections with respiratory viruses and M. pneumoniae were found. In conclusion, the diagnostic value of utilizing NPS/OPS specimen is excellent, and, as the first report in Korea, coinfection with respiratory pathogens were detected at a rate of 9.7% in patients with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded in part by the KOICA IBS program (2018-0119).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We retrospectively analyzed the request forms and RT-PCR assay results of the study subjects, which were exempted from informed consent. This study was approved by the Institutional Review Boards of Seegene Medical Foundation (SMF-IRB-2020-003) and Kyungpook National University Hospital (DGIRB202003001-HE002).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData would be available upon request. Please contact the corresponding author, Nackmoon Sung, PhD via eamil, paratb@gmail.com.